Topical Cyclosporine A and Corneal Wound Healing

Filipec, Martin; Phan, T.-M.; Tz, Zhao; Ba, Rice; Merchant, Altaf; Cs, Foster

doi:10.1097/00003226-199211000-00011

Cited by 16 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To understand the processes responsible for induction of gingival overgrowth, researchers have studied the effects of CSA on gingival cell metabolism 6,18,23 . However, relatively little attention has focused on the effects of CSA on the oral hard tissue, the tooth and the surrounding bony tissue.…”

Section: Discussionmentioning

confidence: 99%

“…For example, one study on rats reported that the primary healing of skin or musculo-fascial incisions was not inhibited by 15 days of CSA (20 mg/kg) administration 4 . Another study showed that topical usage of CSA (2%) did not significantly inhibit epithelial or stromal corneal wound healing 6 . CSA at concentrations of 400 and 800 ng/mL inhibited endothelial migration into wounded porcine aortic monolayers 10 .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Healing following tooth extraction in cyclosporine-fed rats

Gau¹,

Hsieh²,

Shen³

et al. 2005

International Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Healing following tooth extraction in cyclosporine-fed rats

Gau¹,

Hsieh²,

Shen³

et al. 2005

International Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

“…The topical form usually contains 2% percentile of CsA. This dosage has not interfered in corneal wound healing [30].…”

Section: Discussionmentioning

confidence: 99%

The Effect of Cyclosporin A on Cultured Rabbit Subconjunctival Fibroblast Proliferation

Bağcı

Yücel²,

Duranoğlu³

1999

Ophthalmologica

View full text Add to dashboard Cite

The aim of this study was to examine the possible effects of local application of a potent immunosuppressive drug, cyclosporin A (CsA), on fibroblast proliferation in vitro. Rabbit subconjunctival fibroblasts were cultured and incubated with varying doses of CsA (from 0.5 to 5%). Growth inhibition curves were obtained, and cell attachment and reversibility of drug-induced growth inhibition were studied. None of the doses stimulated fibroblast proliferation. CsA inhibited fibroblast proliferation depending on the dose and duration of application. Also, drug-induced growth inhibition decreased depending on dose and duration of application. While the dosage which led to 50% inhibition was found to be 7.2 mg/ml, 4% and higher doses had toxic effects.

show abstract

“…22,23 Previous studies have shown that topical CsA 1-2% can be used safely and effectively in human eyes status post penetrating keratoplasty for allograft rejection, vernal keratoconjunctivitis, keratoconjunctivitis sicca, immune-mediated keratitis, necrotizing scleritis and stromal herpetic keratitis. [24][25][26][27][28][29] Considerable evidence exists that topical cyclosporin A reduces the lacrimal gland infiltrate and improves tear production in keratoconjunctivitis sicca dogs, [30][31][32][33] and a few clinical studies indicate that systemic or topical cyclosporine improves some objective or subjective signs of keratoconjunctivitis sicca in patients with or without Sjogren's syndrome. [34][35][36] Therefore, it appears that cyclosporin A may target the tear deficient aspect of dry eye by modulating the immune reactivity and inflammatory processes of both senescence-related dry eye as well as the dry eye condition associated with Sjogren's syndrome.…”

Section: Discussionmentioning

confidence: 99%

The use of topical cyclosporin A in ocular graft-versus-host-disease

Kiang

Tesavibul

Yee

et al. 1998

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Ocular manifestations of GVHD include keratoconjunctivitis sicca, cicatricial lagophthalmos, sterile conjunctivitis, persistent corneal epithelial defects, corneal ulcers and corneal melting. Conventional initial therapy such as lubrication and topical steroids is directed to treat decreased tear production and ocular surface abnormalities. The purpose of this study was to illustrate the possible benefit of topical cyclosporin A 1% (CsA) as an adjunct in managing ocular surface abnormalities in five cases of GVHD refractory to conventional therapy. Five clinical case reports of chronic GVHD patients in whom conventional therapy was inadequate to stop the progression from its initial presentation are described. Patient presentation varied in severity on a spectrum of mild to moderate diffuse punctate epithelial erosions to sterile necrotizing corneal melts. Although systemic therapy for GVHD consisting of systemic immunosuppressants (ie cyclosporin A and corticosteroids) was given to these patients, this therapy was insufficient in managing the ocular manifestations of the disease. Topical CsA was added to the treatment regimen and the progression of the ocular disease was recorded. The addition of topical CsA 1% probably helped in controlling the epithelial keratitis and melting process in our reported cases and we conclude that topical CsA may be an appropriate modality in managing ocular surface abnormalities in patients with ocular GVHD after conventional treatments have been tried. However, a further randomized clinical prospective study is needed to evaluate the efficacy of topical CsA in managing these problems in GVHD patients.

show abstract

Topical Cyclosporine A and Corneal Wound Healing

Cited by 16 publications

References 0 publications

Healing following tooth extraction in cyclosporine-fed rats

Healing following tooth extraction in cyclosporine-fed rats

The Effect of Cyclosporin A on Cultured Rabbit Subconjunctival Fibroblast Proliferation

The use of topical cyclosporin A in ocular graft-versus-host-disease

Contact Info

Product

Resources

About